Radisys Announces Availability of Industry-first Release 17 Compliant 5G NR Solution
Radisys® Corporation, a global leader of open telecom solutions, today announced its Release 17 compliant 5G NR software solution, extending its award-winning Release 16 Software with advanced features like non-terrestrial networks (NTN) and integrated access and backhaul (IAB) that expands coverage ability for 5G Networks. Release 17 relay node and satellite access capabilities will improve worldwide cellular service availability by enhancing the accessibility of fast and reliable 5G connectivity for unserved and underserved areas. In addition to driving ubiquitous 5G consumer access, Radisys’ Release 17 compliant 5G NR software supports enterprise, infrastructure and public safety use cases including intelligent transportation systems (ITS), aeronautic broadband, maritime, critical communications, fleet management, smart factories, and Internet of Things (IoT) devices.
Radisys’ Connect RAN 5G solution facilitates a flexible 5G network to meet varied deployment requirements and provide universal 5G connectivity for diverse applications and use cases. By deploying Connect RAN 5G software, customers can minimize their development costs and operational and capital expenses while at the same time improving time-to-market and shortening their return on investment.
News Highlights
- Radisys’ Release 17 compliant RAN software continues its proven track record of 5G R&D innovation, enabling 5G Network connectivity for diverse service enabler ultra-reliable low latency communication (URLLC), and eMBB use cases across a wide set of FR1and FR2 bands for multiple deployment and access options.
- Radisys’ Connect RAN 5G software’s NTN feature supports geostationary, medium and low earth orbit (GEO/MEO/LEO) satellite access with flexible and scalable software architecture and well-defined interfaces to SATCOM infrastructure. Radisys’ NTN software empowers OEMs and ODMs to unlock newer business opportunities by leveraging the significant investment being made in SATCOM technology.
- Radisys’ IAB feature enhances centralized (CU) and distributed (DU) units to service relay nodes as 3GPP compliant Donor CUs and Donor DUs. It also includes IAB/Relay node comprising IAB-DU and IAB-MT software that provides end-to-end IAB solution integration with industry-leading platforms.
- Radisys’ Release 17 compliant RAN software provides a foundation for features such as NR positioning, reduced capability (RedCap), and NR SideLink enabling OEMs, ODMs and operators to cost-effectively scale their 5G networks.
“We are excited to launch the first-to-market Release 17 Connect RAN 5G Software delivering expanded 5G connectivity and service accessibility, enabling our customers to unlock newer business opportunities,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “With advanced features like NTN and IAB, Radisys continues to be a leader in delivering ORAN-compliant multi-architecture and multi-platform 5G software to our customers, driving business use cases across a variety of industry verticals.”
Meet with Radisys at MWC Barcelona
See demonstrations of Radisys’ industry-first Release 17 compliant 5G NR Solution, at MWC Barcelona, Stand 5B81. To schedule a meeting with Radisys’ mobility experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005290/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom